Du är här


Apricus Biosciences, Inc.: Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Italy by Bracco SpA

To Be Commercialized in Italy as Vitaros®

SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced the launch of Vitaros®in Italy by
Bracco SpA. Vitaros, Apricus' novel topical on-demand treatment for erectile
dysfunction ("ED"), is also marketed under the trademark Vytaros®in Belgium
and Virirec(TM)in Spain. This is the seventh country in the European Union in
which the product has been launched, including France, Italy, Germany, the
United Kingdom, Spain, Belgium and Sweden. In total, Vitaros is currently
approved under the European Decentralized Procedure ("DCP") in twenty-two
countries, of which fourteen have further approved Vitaros for
commercialization at the national phase level of the DCP approval process.

Richard Pascoe, Chief Executive Officer of Apricus, commented, "We are pleased
to announce Bracco's launch of Vitaros, the first on-demand topical
treatment, in Italy, Europe's second largest ED treatment market which Bracco
estimates to be approximately $135 million. As another contributor towards
the positive momentum of commercialization by our partners, which recently
produced 103% growth in units quarter over quarter, Bracco plans to implement
a strong promotional strategy targeted at physicians across Italy. With this
news, the product is now launched in the five largest markets in Europe."

In December 2010, Apricus signed an exclusive license agreement with Bracco to
market Vitaros, in Italy, Vatican City and San Marino (the "Territory").
Under the terms of the agreement, Apricus has received $1.3 million in
up-front and milestone payments from Bracco. Apricus is also eligible to
receive milestone payments on future sales, plus double-digit tiered
royalties based on Bracco's net sales of the product in the Territory. In
exchange, Bracco has the exclusive right to commercialize Vitaros in the
Territory. In addition, Bracco has agreed to certain minimum marketing
commitments for Vitaros.

About Bracco

Bracco is an international Group active in the healthcare sector through
Bracco Imaging (Diagnostic Imaging), Pharma (prescription and over the
counter drugs), Acist Medical Systems (medical devices and advanced imaging
agents injection systems based in Minneapolis, USA), and the Centro
Diagnostico Italiano diagnostic clinic in Milan. It has more than 3,300
employees and annual total consolidated revenues of over 1.1 billion euros,
of which 75% is from international sales, and it is present worldwide. In the
Research and Innovation area, the company invests approximately 9% of
reference turnover in the imaging diagnostics and medical devices sectors and
has a portfolio comprising over 1,800 patents.

For further information on Bracco and its subsidiaries,

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (Nasdaq:APRI) is a biopharmaceutical company
advancing innovative medicines in urology and rheumatology. Apricus has
initiated a Phase 2b trial for fispemifene, a selective estrogen receptor
modulator for the treatment of symptomatic male secondary hypogonadism, and
plans to conduct additional studies in other urological conditions. Apricus
recently completed enrollment in a Phase 2a trial for RayVa(TM), its product
candidate for the treatment of the circulatory disorder Raynaud's phenomenon.
Apricus' lead commercial product, Vitaros®, for the treatment of erectile
dysfunction, is approved in Europe and Canada and is being commercialized in
several countries in Europe. Apricus' marketing partners for Vitaros include
Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz),
Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires
Majorelle. Apricus' second-generation room temperature Vitaros is under

For further information on Apricus, visithttp://www.apricusbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act, as amended. Statements in this
press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things: references to
the potential for Vitaros to achieve commercial success generally or in any
specific territory, including Italy; the potential for the DCP approvals to
enhance the value of Vitaros for Apricus' partners and shareholders; the size
of the commercial opportunity for Vitaros; Vitaros' ability to capture market
share in Europe; and the potential for Apricus to receive future milestone
and royalty revenue. Actual results could differ from those projected in any
forward-looking statements due to a variety of reasons that are outside of
Apricus' control, including, but not limited to: Apricus' dependence on
Bracco to carry out the commercial launch or grow sales of Vitaros in Italy;
the effect of the previously-reported out-of-stock situation for Vitaros in
Germany and the potential that Apricus' partner there, Sandoz, does not
resume ordering product for Germany or other countries pending the results of
an ongoing out-of-specification investigation by our contract manufacturer;
Apricus' ability to have its product Vitaros be approved by relevant
regulatory authorities in Europe and in other countries, such as national
phase approvals for Vitaros in the additional CMS territories; its ability to
further develop its product Vitaros for the treatment of ED, such as the room
temperature version of Vitaros, as well as the timing of such events;
competition in the ED market and other markets in which Apricus and its
partners operate; Apricus' ability to obtain and maintain intellectual
property protection for the product; Apricus' ability to raise additional
funding that it may need to continue to pursue its commercial and business
development plans; the fluctuation of currency exchange rates; the potential
for adverse reactions to the product; and market conditions. These
forward-looking statements are made as of the date of this press release, and
Apricus assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those projected in
the forward-looking statements. Readers are urged to read the risk factors
set forth in Apricus' most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q, and other filings made with the SEC.
Copies of these reports are available from the SEC's website atwww.sec.gov or
without charge from Apricus.

CONTACT: Matthew Beck
The Trout Group
(646) 378-2933


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.